Latest Regulatory News

Island Pharmaceuticals has raised $350,000 through an options exercise by substantial shareholder MWP Partners, reinforcing confidence in its antiviral drug development pipeline.

Reef Casino Trust has received a revised $184.3 million takeover offer from Morris Group, intensifying a competitive bidding process with Iris Cairns Property. Unitholders are advised to hold off on decisions as the Independent Board Committee evaluates the proposals.

Syntara Limited is set to update investors on the clinical progress of its lead drug candidate amsulostat, targeting myelofibrosis, in a webinar scheduled for 11 August 2025. The company highlights recent regulatory milestones and advancing trials.

Syntara Limited has received FDA guidance recommending a Phase 2 controlled trial for its lead drug amsulostat in myelofibrosis, setting the stage for a pivotal Phase 3 study. The company is poised to refine its clinical strategy while advancing a diverse pipeline with key data milestones ahead.

Dalaroo Metals has successfully completed a placement raising $877,500 through the issue of 35.1 million shares and 11.7 million free attaching options, bolstering its capital position within existing regulatory limits.

Zeotech Limited has secured a binding offtake term sheet with MSI, granting exclusive rights to supply and market its kaolin products across key Asian markets, underpinning its Toondoon Kaolin Project development.

Cyclone Metals Limited has completed a comprehensive Scoping Study for its Iron Bear magnetite project in Canada, revealing strong economic potential and a strategic funding partnership with Vale S.A. The study outlines multiple production scenarios and highlights the project's alignment with low-carbon steelmaking trends.

Santana Minerals has raised A$63 million through a fully underwritten placement and a Share Purchase Plan to fast-track development of its Bendigo-Ophir Gold Project, attracting strong support from international and domestic investors.

Iress Limited reported a robust first half of 2025 with strong earnings growth and reduced leverage, driven by core business strength and strategic divestments. The company is poised to capitalize on regulatory tailwinds and technology demand in wealth and trading sectors.

JB Hi-Fi Limited reported a robust FY2025 with revenue up 10% to $10.55 billion and net profit after tax rising 5.4% to $462.4 million. The company declared a fully franked final dividend and a special dividend, while announcing a CEO succession plan.

Noxopharm Limited has successfully completed the second dose cohort in its HERACLES Phase 1 trial for SOF-SKN™, confirming safety and tolerability and moving forward to a higher dose. This progress marks a key step in developing a novel autoimmune disease treatment.

Charter Hall Social Infrastructure REIT has reported a statutory profit of $71 million for FY25, reversing last year’s loss, while advancing its portfolio through key acquisitions and refinancing.